Photosensitization of a subcutaneous tumour by the natural anthraquinone parietin and blue light

• Published in: Scientific reports Vol. 11; no. 1; p. 23820
• Main Authors: Mugas, María Laura, Calvo, Gustavo, Marioni, Juliana, Céspedes, Mariela, Martinez, Florencia, Vanzulli, Silvia, Sáenz, Daniel, Di Venosa, Gabriela, Nuñez Montoya, Susana, Casas, Adriana
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 10-12-2021; Nature Publishing Group; Nature Portfolio
• Subjects: 631/154; 631/67; 631/80; Animals; Anthraquinone; Anthraquinones - chemistry; Anthraquinones - pharmacology; Carcinoma; Cell Line, Tumor; Cell migration; Cell Movement - drug effects; Cell Movement - radiation effects; Cell Proliferation - drug effects; Cell Proliferation - radiation effects; Dimethyl sulfoxide; Disease Models, Animal; Dose-Response Relationship, Drug; Emodin - chemistry; Emodin - pharmacology; Female; Fluorescence; Fluorescence microscopy; Histology; Humanities and Social Sciences; Illumination; Leukemia; Light; Localization; Mammary gland; Metastases; Mice; multidisciplinary; Photochemicals; Photochemotherapy - methods; Photodynamic therapy; Photosensitization; Photosensitizing Agents - chemistry; Photosensitizing Agents - pharmacology; Science; Science (multidisciplinary); Skin; Skin Neoplasms - etiology; Skin Neoplasms - metabolism; Skin Neoplasms - therapy; Stratum corneum; Treatment Outcome; Tumor Cells, Cultured; Tumors; Variance analysis
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-03339-z

Photodynamic therapy (PDT) is an anticancer treatment involving administration of a tumour-localizing photosensitizer, followed by activation by light of a suitable wavelength. In previous work, we showed that the natural anthraquinone (AQ) Parietin (PTN), was a promising photosensitizer for photodynamic therapy of leukemic cells in vitro. The present work aimed to analyze the photosensitizing ability of PTN in the mammary carcinoma LM2 cells in vitro and in vivo in a model of subcutaneously implanted tumours. Photodynamic therapy mediated by parietin (PTN-PDT) (PTN 30 µM, 1 h and 1.78 J/cm
2
of blue light) impaired cell growth and migration of LM2 cells in vitro. PTN per se induced a significant decrease in cell migration, and it was even more marked after illumination (migration index was 0.65 for PTN and 0.30 for PTN-PDT, *p < 0.0001, ANOVA test followed by Tukey’s multiple comparisons test), suggesting that both PTN and PTN-PDT would be potential inhibitors of metastasis. Fluorescence microscopy observation indicated cytoplasmic localization of the AQ and no fluorescence at all was recorded in the nuclei. When PTN (1.96 mg) dissolved in dimethyl sulfoxide was topically applied on the skin of mice subcutaneously implanted with LM2 cells, PTN orange fluorescence was strongly noticed in the stratum corneum and also in the inner layers of the tumour up to approximately 5 mm. After illumination with 12.74 J/cm
2
of blue light, one PDT dose at day 1, induced a significant tumour growth delay at day 3, which was not maintained in time. Therefore, we administered a second PTN-PDT boost on day 3. Under these conditions, the delay of tumour growth was 28% both on days 3 and 4 of the experiment (*p < 0.05 control vs. PTN-PDT, two-way ANOVA, followed by Sidak’s multiple comparisons test). Histology of tumours revealed massive tumour necrosis up to 4 mm of depth. Intriguingly, a superficial area of viable tumour in the 1 mm superficial area, and a quite conserved intact skin was evidenced. We hypothesize that this may be due to PTN aggregation in contact with the skin and tumour milieu of the most superficial tumour layers, thus avoiding its photochemical properties. On the other hand, normal skin treated with PTN-PDT exhibited slight histological changes. These preliminary findings encourage further studies of natural AQs administered in different vehicles, for topical treatment of cutaneous malignancies.